Last $2.00 USD
Change Today 0.00 / 0.00%
Volume 0.0
IMCL On Other Exchanges
Symbol
Exchange
OTC BB
As of 8:10 PM 07/18/14 All times are local (Market data is delayed by at least 15 minutes).

immunoclin corp (IMCL) Snapshot

Open
$2.00
Previous Close
$2.00
Day High
$2.00
Day Low
$2.00
52 Week High
03/5/14 - $8.00
52 Week Low
06/30/14 - $1.45
Market Cap
52.9M
Average Volume 10 Days
20.0
EPS TTM
--
Shares Outstanding
26.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNOCLIN CORP (IMCL)

Related News

No related news articles were found.

immunoclin corp (IMCL) Related Businessweek News

No Related Businessweek News Found

immunoclin corp (IMCL) Details

Immunoclin Corporation provides comprehensive, clinical, and basic science research services to pharmaceutical, biotechnology, and food industries. It is involved in the research and development on products, such as MIRA, an algorithm to analyze the multi-variant data to identify people who are at risk of having heart attack; and GARD, a genetic test for multiple genetic polymorphisms associated with increased risk of the most common form of dementia. Immunoclin Corporation is also engaged in the research and development of PRIMALEUKIN, an antibacterial, anti-fungal, and antiviral agent, harnessing and amplifying the body’s own natural defense against, and recovery from, infection; DACTELLIGENCE, a technology and newly patented concept in bio-sensing to challenge detection platforms in multiple diagnostic fields; and GastroWellBeing, an immunological food supplement. The company was formerly known as Pharma Investing News, Inc. and changed its name to Immunoclin Corporation in December 2013. Immunoclin Corporation is headquartered in Beverly Hills, California.

immunoclin corp (IMCL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $20.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $20.0K
Chief Scientific Officer and Director
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

immunoclin corp (IMCL) Key Developments

ImmunoClin Corporation will Change its Ticker to IMCL from IMCL.E

Effective July 18, 2014, ImmunoClin Corporation will change its OTC Bulletin Board stock ticker symbol to IMCL from IMCL.E.

Immunoclin Corporation Appoints Turner, Stone & Company, LLP Replacing Sadler, Gibb & Associates, LLC as Auditors

On July 2, 2014, Immunoclin Corporation dismissed Sadler, Gibb & Associates, LLC as the company’s principal accountant. The company’s board of directors approved the dismissal of Sadler Gibb on the same date. On July 3, 2014, the company’s board of directors approved the engagement of Turner, Stone & Company, LLP as its principal accountant to audit the company’s financial statements as successor to Sadler Gibb.

ImmunoClin Corporation will Change its Ticker to IMCLE from IMCL

Effective June 18, 2014, ImmunoClin Corporation will change its OTC Bulletin Board stock ticker symbol to IMCLE from IMCL.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMCL:US $2.00 USD 0.00

IMCL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMCL.
View Industry Companies
 

Industry Analysis

IMCL

Industry Average

Valuation IMCL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOCLIN CORP, please visit www.pharmainvestingnews.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.